Newel Health and Gerresheimer have announced a strategic collaboration aimed at helping pharmaceutical and biotech companies design, develop, and scale integrated drug–digital solutions, combining software as a medical device (SaMD), connected delivery systems, and real-world data capabilities.

The partnership brings together Newel Health’s H-Core platform—powering regulated digital medical devices, AI-enabled analytics, and patient-centric experiences—with Gerresheimer’s expertise in drug delivery systems, pharmaceutical packaging, connected devices, and digital health infrastructure.

By leveraging real-world data and connected technologies, Newel Health and Gerresheimer aim to support a shift toward more continuous, objective, and personalized patient care. The collaboration reflects a broader industry move toward integrated therapeutic models, where software, devices, and medicines are designed together rather than in isolation.

Spotlight at Frontiers Health: Building the Next Layer of Digital Medicine

Both Newel Health and Gerresheimer are active contributors to the Frontiers Health ecosystem, where discussions increasingly focus on the convergence of software, hardware, and pharma into scalable healthcare solutions.

Gerresheimer joined Frontiers Health 2025 as a Silver Partner, highlighting its ambition to extend beyond traditional packaging and delivery into integrated digital health solutions. At the event, its leadership emphasized the importance of connecting drug delivery systems with digital layers to enable better patient outcomes and more efficient healthcare pathways. Through sessions and interviews, Gerresheimer explored how combining connected devices with data and software can unlock real-world evidence generation and therapy optimization—key themes aligned with its collaboration with Newel Health.

Newel Health, participating as a strategic partner, has contributed to conversations around digital precision medicine and the role of regulated digital therapeutics in clinical pathways. Its presence at Frontiers Health highlights a focus on scalable digital medical devices and using AI insights to improve patient care, especially in cardiometabolic and chronic diseases.

Across multiple sessions and contributions—from discussions on innovative modalities and scalable healthcare transformation to ecosystem dialogues where software meets hardware and pharma —the two companies have helped illustrate a shared vision: a future where integrated therapeutic solutions are not only technically feasible but also operationally scalable and clinically meaningful.